Synmosa Biopharma Corporation (TPEX:4114)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.15
+0.10 (0.33%)
May 29, 2026, 1:30 PM CST

Synmosa Biopharma Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
806.68821.85684.68594.83799.09303.86
Depreciation & Amortization
339.4335.64335.41334.83315.64297.29
Other Amortization
7.567.566.565.094.744.77
Loss (Gain) From Sale of Assets
0.650.660.44-0.12-281.43-11.86
Asset Writedown & Restructuring Costs
12.0712.070.2410.8615.228.21
Loss (Gain) From Sale of Investments
-82.37-64.7463.83-49.82-50.41-4.75
Loss (Gain) on Equity Investments
28.9926.3813.7810.3316.5616.4
Stock-Based Compensation
31.735.8714.6417.2122.4710.64
Provision & Write-off of Bad Debts
1.220.61-0.496.743.411.82
Other Operating Activities
-221.91-234.34-188.89-98.04-59.33-147.25
Change in Accounts Receivable
-102.55-135.03-130.66-27.87-244.16-77.74
Change in Inventory
-344.6-486.49-110.39-305.39-120.9416.87
Change in Accounts Payable
41.1189.4947.31-8.09147.9565.26
Change in Unearned Revenue
-80.24-74.01-5.391.2146.36-2.44
Change in Other Net Operating Assets
15.976.0449.5520.1515.08-26.21
Operating Cash Flow
453.62411.57780.62511.93630.25454.86
Operating Cash Flow Growth
-47.55%-47.28%52.49%-18.77%38.56%78.80%
Capital Expenditures
-182.2-255.44-214.52-207.04-129.3-93.06
Sale of Property, Plant & Equipment
0.140.143.131.62305.18240.57
Cash Acquisitions
----48.83-95.86-7.52
Sale (Purchase) of Intangibles
-34.28-25.7-55.13-53.48-55.03-49.07
Investment in Securities
-580.03-398.4-107.35-402.88-96.92-2.12
Other Investing Activities
-166.4615.8637.08-7.252.59-15.48
Investing Cash Flow
-962.81-663.54-336.8-717.87-69.3373.33
Short-Term Debt Issued
-753.513.62127.07-133
Long-Term Debt Issued
-189.81159.01493350-
Total Debt Issued
918.31943.31172.62620.07350133
Short-Term Debt Repaid
--741.93--50-179.76-
Long-Term Debt Repaid
--247.74-72.09-1,532-344.65-381.84
Total Debt Repaid
-1,031-989.66-72.09-1,582-524.41-381.84
Net Debt Issued (Repaid)
-112.96-46.35100.54-962.15-174.41-248.84
Issuance of Common Stock
51.641,109-95040.230.61
Repurchase of Common Stock
-97.87----108.97-51.64
Common Dividends Paid
-272.61-272.61-228.74-194.43-148.64-79.98
Other Financing Activities
158.48174.52-59.35243.8343.8482.28
Financing Cash Flow
-273.33964.2-187.5537.24-347.95-297.57
Foreign Exchange Rate Adjustments
-6.64-7.111.27-0.396.52-0.81
Net Cash Flow
-789.16705.14267.55-169.09219.48229.82
Free Cash Flow
271.43156.14566.1304.89500.95361.81
Free Cash Flow Growth
-56.57%-72.42%85.68%-39.14%38.46%261.83%
Free Cash Flow Margin
4.26%2.52%10.20%5.93%11.42%11.18%
Free Cash Flow Per Share
0.540.321.220.681.160.83
Cash Interest Paid
62.0462.0460.0266.9759.2951.82
Cash Income Tax Paid
232.56232.56198.33172.0869.7665.01
Levered Free Cash Flow
-188.2-39.26426.14148.45362.14420.14
Unlevered Free Cash Flow
-149.06-0.48462.45190.44399.33452.62
Change in Working Capital
-470.38-530-149.57-319.99-155.72-24.26